Sexually Transmitted Diseases

The recommendation means more patients will be able to access PrEP at no cost. However, it likely won’t be enough to dramatically boost PrEP usage without other systemic advances.

The FDA has expanded the patient population and issued updated drug interactions, warnings, and precautions for Biktarvy.

A recent animal trial reveals that MK-8591 offers protection against SHIV at lower and more infrequent doses than current PrEP options, renewing hope for more choices in the future.

Experts provide community physicians treating HIV with practical advice for screening, diagnosing, and managing patients with HIV.

A phase 1 study demonstrated that pembrolizumab is appropriate for FDA-approved indications and clinical trials among people living with HIV and advanced cancer.

Failure to fill prescriptions is a common issue among adolescents diagnosed with sexually transmitted infections in emergency departments, according to a new research letter.

The HIV Medicine Association reports that the recommendation, once implemented in 2021, will require insurers to cover PrEP with no cost-sharing to patients.

Meeting goals to eliminate HIV, viral hepatitis, and sexually transmitted infections by 2030 will require accelerated efforts, according to a progress report from the WHO.

Very early introduction of ART may alter HIV immune response long term, with implications for development of effective vaccine.

Individuals at a higher risk of contracting HIV showed greater adherence to PrEP and moved toward less risky partnership types over time.

Nearly 500 children are infected with HIV after being put at risk due to poor medical practices in a country where violence against individuals living with HIV is still an issue.

A look at up-and-coming HIV drugs in development.

Following the launch of the campaign in March 2015, investigators saw a 77% increase in HIV testing compared with January and February of the same year in Beijing.

For the first time, patients with new HIV diagnoses have a 2-drug regimen option.

In the first-in-human trial of the replication-defective HSV529, the vaccine was well-tolerated and elicited antibody and T-cell responses in HSV seronegative adults.

Generic PrEP drugs offer a cost-effective way for people to reduce their risk of HIV, though some worry about the authenticity of drugs purchased online.

The likelihood of using PrEP is significantly influenced by recommendations from health care providers and concerns about side effects, according to a recent study of heterosexual individuals in Philadelphia.

Is there a cure? How long until we find it? And will it work for the majority of people living with HIV?

A team of investigators conducted 284 autopsies to determine Cryptococcus-associated mortality in 2 areas with a high HIV prevalence.

A recent study found that at the 18-month mark, PLWH on dolutegravir gained 6.0 kg compared with 2.6 kg for NNRTI (p

The adjusted odds for having oropharyngeal gonorrhea were 1.46-fold for men with ≥4 kissing-only partners and 1.81-fold for men with ≥4 kissing-with-sex partners.

Women are quite receptive to learning about PrEP in the right environment, but some providers have a long way to go in terms of education.

Agreement between Gilead and Trump administration promises more drugs for at-risk patients.

Following a rise in sexually transmitted infection diagnoses in recent years, NIAID is awarding grants for research into syphilis, gonorrhea, and chlamydia vaccine candidates.

In a tiny number of cases, treating HIV with ART actually makes CD4+ T cell levels fall.

Compared with no pharmacist involvement, a greater number of appropriate antiretroviral regimens were initiated with partial pharmacist involvement (62% vs. 32%, p = 0.0096).

A survey of nearly 300 pharmacy students found that 91% were aware of PrEP and 61% reported high familiarity with PrEP prescription guidelines, but knowledge gaps still remain.

Understanding barriers and facilitators of PrEP could help improve adherence among young men and transgender women of color, a recent study found.

An infamous beauty procedure is causing concern over spa safety failures after 2 clients were diagnosed with HIV.

The final results of the PARTNER study have been published in the journal The Lancet and confirm that an undetectable viral load on HIV treatment renders an individual sexually non-infectious.